REFERENCES
Nefazodone: A better tolerated option than TCAs for major depression. Drugs Ther Perspect 10:1–7, 1997
Zimmerman HJ: Hepatotoxicity. Dis Month 39:675–787, 1993
Cosme A, Barrio J, Lobo C, Gil Y, Castiella A, Arenas JI: Acute cholestasis by fluoxetine. Am J Gastroenterol 91:2449–2450, 1996
Lee WM: Acute liver failure. N Engl J Med 329:1862–1872, 1993
Farrel GC: Pathogenesis of drug-induced liver disease. In AASLD Postgraduate Course. Liver Injury Update: Clinical Implications and Mechanism Role of Cells of the Liver. 1997, pp 37–47
Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281–302, 1998
Barbhaiya RH, Buch AB, Greene DS: Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 42:573–581, 1996
Chu AG, Gunsolly BL, Summers RW, Alexander B, McChesney C, Tanna VL: Trazodone and liver toxicity. Ann Intern Med 99:128–129, 1983
Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN: The safety profile of nefazodone. J Clin Psychiatry 57( suppl 2):31–38, 1996
Rights and permissions
About this article
Cite this article
Lucena, M.I., Andrade, R.J., Gomez-Outes, A. et al. Case Report: Acute Liver Failure After Treatment with Nefazodone. Dig Dis Sci 44, 2577–2579 (1999). https://doi.org/10.1023/A:1026620029470
Issue Date:
DOI: https://doi.org/10.1023/A:1026620029470